Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non-Muscle-Invasive Bladder Cancer

European Urology, Supplements

Volumn 8, Issue 5, 2009, Pages 458-463

  Holmäng, Sten ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Chemotherapy; Single instillation

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; LIDOCAINE; MITOMYCIN; PLACEBO;

BLADDER BIOPSY; BLADDER CANCER; BLADDER CATHETERIZATION; BLADDER DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL PROTOCOL; DIATHERMY; DISEASE SEVERITY; DRUG EFFECT; DRUG INSTILLATION; FAT NECROSIS; HISTOPATHOLOGY; HOSPITAL COST; HOSPITALIZATION; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 60049090568     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.12.003     Document Type: Review

References (33)

1. Burnand K.G., Boyd P.J.R., Mayo M.E., Shuttleworth K.E.D., and Lloyd-Davies R.W. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48 (1976) 55-59
2. Gavrell G.J., Lewis R.W., Meehan W.L., and Leblanc G.A. Intravesical thiotepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120 (1978) 410-411
3. Abrams P.H., Choa R.G., Gaches C.G.C., Ashken M.H., and Green N.A. A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Br J Urol 53 (1981) 585-587
4. Zincke H., Utz D.C., Taylor W.F., Myers R.P., and Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129 (1983) 505-509
5. MRC Working Party on Urological Cancer. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. Br J Urol 57 (1985) 680-685
6. Tolley D.A., Hargreave T.B., Smith P.H., et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on superficial bladder cancer (Urological Cancer Working Party). Br J Urol 296 (1988) 1759-1761
7. Van der Meijden A.P.M., Kurth K.-H., Oosterlinck W., Debruyne F.M.J., and Members of the EORTC Genito-Urinary Group. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Phamacol 30 Suppl (1992) 95-98
8. Oosterlinck W., Kurth K.-H., Schröder F., et al. A prospective European Organization for research and treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
9. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Br J Urol 73 (1994) 632-638
10. Tolley D.A., Parmar M.K.B., and Grigor K.M. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233-1238
11. Ali-El-Dein B., Nabeeh A., El-Baz M., Shamaa S., and Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79 (1997) 731-735
12. Solsona E., Iborra I., Ricos J.V., Monros J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin c instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161 (1999) 1120-1123
13. Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation of interferon-alfa or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol 161 (1999) 1133-1136
14. Rajala P., Kaasinen E., Raitanen M., et al. Perioperative single-dose instillation of epirubicin or interferon-alfa after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-Finnbladder III long-term results. J Urol 168 (2002) 981-985
15. Okamura K., Ono Y., Kinukawa T., et al. Randomized study of single early instillation of (2″R)-4′-0-tetrahydropyranol-doxorubicin for a single superficial bladder carcinoma. Cancer 94 (2002) 2363-2368
16. Berrum-Svennung I., Granfors T., Jahnson S., Boman H., and Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179 (2008) 101-106
17. Sylvester R.J., Oosterlinck W., and van der Meijden A.P.M. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
18. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
19. Popart R.J.M., Goodall J., Coptcoat M.J., et al. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation. Br J Urol 74 (1994) 195-199
20. Hedelin H., Holmäng S., and Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36 (2002) 344-347
21. Doherty A.P., Trendell-Smith N., Stirling R., Rogers H., and Bellringer J. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int 83 (1999) 420-423
22. Patterson A.L., Greenberg R.E., Weems L., et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56 (2000) 232-235
23. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of cancer randomized trials with mitomycin c and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153 (1995) 934-941
24. Hendricksen K., Witjes W.P.J., Idema J.G., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53 (2008) 984-991
25. Cai T., Nesi G., Tinacci G., et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 180 (2008) 110-115
26. Kaasinen E., Rintala E., Hellström P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
27. Holmäng S., Hedelin H., Anderström C., Holmberg E., and Johansson S.L. Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period. Scand J Urol Nephrol 34 (2000) 95-101
28. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
29. Brausi M.A., Gavioli M., Peracchia G., et al. Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumours (NMIBT): experience of a single institution. Eur Urol Suppl 7 (2008) 180 abstract 437
30. Klein F.A., and Whitmore W.F. Bladder papilloma: therapeutic and cost effect of outpatient department management. Urology 18 (1981) 247-249
31. Donat S.M., North A., Dalbagni G., and Herr H.W. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171 (2004) 636-639
32. Holmäng S., Aldenborg F., and Hedelin H. Extirpation and fulguration of multiple superficial bladder tumour recurrences under intravesical lignocaine anaesthesia. Br J Urol 73 (1994) 177-180
33. Engberg A., Spångberg A., and Urnes T. Transurethral resection of bladder tumors under local anesthesia. Urology 22 (1983) 385-387